Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 37.00 | |
2 mg | In stock | $ 53.00 | |
5 mg | In stock | $ 87.00 | |
10 mg | In stock | $ 143.00 | |
25 mg | In stock | $ 259.00 | |
50 mg | In stock | $ 389.00 | |
100 mg | In stock | $ 579.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 108.00 |
Description | JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. |
Targets&IC50 | CB1 receptor:1.5 nM |
In vivo | JD5037, when administered at a dosage of 3 mg/kg/day intraperitoneally (i.p.), effectively induces uniform reductions in body weight and mitigates high-fat diet (HFD)-induced hyperglycemia, hepatic injury, and steatosis in obese Magel2-null mice. Likewise, oral administration of JD5037 (3 mg/kg/day, p.o.) significantly diminishes tumor size and eliminates tumors in DEN-treated mice. Moreover, JD5037 reduces anandamide (AEA) levels in hepatocellular carcinoma (HCC) samples from mice. |
Animal Research | Mice: JD-5037 is formulated in vehicle (V; 1% Tween80, 4% DMSO, 95% Saline). Obese mice are treated chronically (28 d) with vehicle (V; 1% Tween80, 4% DMSO, 95% Saline), JD5037, or SLV319 at a dose of 3 mg/kg, i.p. Body weight and food intake are monitored daily. Mice are euthanized by cervical dislocation under anesthesia; the brain, hypothalamus, liver, and combined fat pads are removed, weighed, and snap-frozen, and trunk blood is collected for determining the endocrine and biochemical parameters |
Synonyms | JD 5037 |
Molecular Weight | 572.51 |
Formula | C27H27Cl2N5O3S |
CAS No. | 1392116-14-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (87.33 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JD-5037 1392116-14-1 GPCR/G Protein Cannabinoid Receptor JD5037 inhibit JD 5037 Inhibitor inhibitor